Ebb & Flow

BioMarin's first announcement related to Orapred, the flagship of its new pediatrics focus, wasn't a great one, as the company expects no revenue contribution from the pediatric asthma drug in the second half. Moreover, there's a possibility that BioMarin (BMRN; SWX:BMRN) could be on the hook for any product returns.

BMRN gained Orapred through its purchase of the Ascent Pediatrics business of Medicis (MRX), which was announced in April and completed in May (see BioCentury, April 26). BMRN had expected the drug to post full year sales of $42 million. In the first half, MRX booked about $13.4 million in sales and BMRN booked about $4.6 million, for total first half sales of $18 million. ...